Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; REACH Registry Investigators..

JAMA. 2012 Oct 3;308(13):1340-9. doi: 10.1001/jama.2012.12559.

PMID:
23032550
2.

β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial.

Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, Montalescot G, Hsu A, Fox KA, Lincoff AM.

Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):872-81. doi: 10.1161/CIRCOUTCOMES.114.001073.

3.

β-blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure.

Ozasa N, Morimoto T, Bao B, Furukawa Y, Nakagawa Y, Kadota K, Iwabuchi M, Shizuta S, Shiomi H, Tazaki J, Natsuaki M, Kimura T; CREDO-Kyoto Registry Investigators..

Int J Cardiol. 2013 Sep 30;168(2):774-9. doi: 10.1016/j.ijcard.2012.10.001.

PMID:
23127614
4.

Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.

Sorbets E, Labreuche J, Simon T, Delorme L, Danchin N, Amarenco P, Goto S, Meune C, Eagle KA, Bhatt DL, Steg PG.

Eur Heart J. 2014 Jul;35(26):1760-8. doi: 10.1093/eurheartj/ehu078.

PMID:
24616336
5.

One-year cardiovascular event rates in outpatients with atherothrombosis.

Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators..

JAMA. 2007 Mar 21;297(11):1197-206.

PMID:
17374814
6.

Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.

Demers C, McMurray JJ, Swedberg K, Pfeffer MA, Granger CB, Olofsson B, McKelvie RS, Ostergren J, Michelson EL, Johansson PA, Wang D, Yusuf S; CHARM Investigators..

JAMA. 2005 Oct 12;294(14):1794-8.

PMID:
16219883
7.

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.

Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, Wilson PW, Alberts MJ, D'Agostino R, Liau CS, Mas JL, Röther J, Smith SC Jr, Salette G, Contant CF, Massaro JM, Steg PG; REACH Registry Investigators..

JAMA. 2010 Sep 22;304(12):1350-7. doi: 10.1001/jama.2010.1322.

PMID:
20805624
8.

Preoperative β-blocker use in coronary artery bypass grafting surgery: national database analysis.

Brinkman W, Herbert MA, O'Brien S, Filardo G, Prince S, Dewey T, Magee M, Ryan W, Mack M.

JAMA Intern Med. 2014 Aug;174(8):1320-7. doi: 10.1001/jamainternmed.2014.2356.

PMID:
24934977
10.

Prognostic impact of ß-blocker use in patients with stable coronary artery disease.

Bauters C, Lemesle G, Meurice T, Tricot O, de Groote P, Lamblin N.

Heart. 2014 Nov;100(22):1757-61. doi: 10.1136/heartjnl-2014-305719.

PMID:
24947319
11.

Nonobstructive coronary artery disease and risk of myocardial infarction.

Maddox TM, Stanislawski MA, Grunwald GK, Bradley SM, Ho PM, Tsai TT, Patel MR, Sandhu A, Valle J, Magid DJ, Leon B, Bhatt DL, Fihn SD, Rumsfeld JS.

JAMA. 2014 Nov 5;312(17):1754-63. doi: 10.1001/jama.2014.14681.

12.

Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial.

Muhlestein JB, Lappé DL, Lima JA, Rosen BD, May HT, Knight S, Bluemke DA, Towner SR, Le V, Bair TL, Vavere AL, Anderson JL.

JAMA. 2014 Dec 3;312(21):2234-43. doi: 10.1001/jama.2014.15825.

PMID:
25402757
13.

Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry.

Steg PG, Greenlaw N, Tendera M, Tardif JC, Ferrari R, Al-Zaibag M, Dorian P, Hu D, Shalnova S, Sokn FJ, Ford I, Fox KM; Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease (CLARIFY) Investigators..

JAMA Intern Med. 2014 Oct;174(10):1651-9. doi: 10.1001/jamainternmed.2014.3773.

PMID:
25110899
14.

Efficacy of Long-Term β-Blocker Therapy for Secondary Prevention of Long-Term Outcomes After Coronary Artery Bypass Grafting Surgery.

Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K, Rao C, Wang W, Sun H, Hu S, Zheng Z.

Circulation. 2015 Jun 23;131(25):2194-201. doi: 10.1161/CIRCULATIONAHA.114.014209.

15.

Association of β-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study.

Andersson C, Mérie C, Jørgensen M, Gislason GH, Torp-Pedersen C, Overgaard C, Køber L, Jensen PF, Hlatky MA.

JAMA Intern Med. 2014 Mar;174(3):336-44. doi: 10.1001/jamainternmed.2013.11349. Erratum in: JAMA Intern Med. 2015 Jun;175(6):1070.

PMID:
24247428
16.

Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure.

Bunch TJ, Muhlestein JB, Bair TL, Renlund DG, Lappé DL, Jensen KR, Horne BD, Carter MA, Anderson JL; Intermountain Heart Collaborative Study Group..

Am J Cardiol. 2005 Apr 1;95(7):827-31.

PMID:
15781009
17.

2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study.

Bangalore S, Gong Y, Cooper-DeHoff RM, Pepine CJ, Messerli FH.

J Am Coll Cardiol. 2014 Aug 26;64(8):784-93. doi: 10.1016/j.jacc.2014.05.044.

18.

Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.

Mentz RJ, Allen BD, Kwasny MJ, Konstam MA, Udelson JE, Ambrosy AP, Fought AJ, Vaduganathan M, O'Connor CM, Zannad F, Maggioni AP, Swedberg K, Bonow RO, Gheorghiade M.

Eur J Heart Fail. 2013 Jan;15(1):61-8. doi: 10.1093/eurjhf/hfs139.

19.

Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California.

Van Den Eeden SK, Albers KB, Davidson JE, Kushida CA, Leimpeter AD, Nelson LM, Popat R, Tanner CM, Bibeau K, Quesenberry CP.

Sleep. 2015 Jul 1;38(7):1009-15. doi: 10.5665/sleep.4800.

20.

Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.

Carrero JJ, Evans M, Szummer K, Spaak J, Lindhagen L, Edfors R, Stenvinkel P, Jacobson SH, Jernberg T.

JAMA. 2014 Mar 5;311(9):919-28. doi: 10.1001/jama.2014.1334.

PMID:
24595776
Items per page

Supplemental Content

Support Center